|
|
|
|
|
|
Sponsored by: |
Norris Comprehensive Cancer Center |
Information provided by: | Norris Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT00183846 |
This study is for people with advanced cancer of the digestive tract and cancer that cannot be completely removed by surgery. Radiation therapy is commonly used in the treatment of these types of cancer in combination with a chemotherapy drug, called 5-fluorouracil (5-FU). In this study, doctors will administer the standard dose of radiation therapy in combination with an investigational chemotherapy drug, called irinotecan. Irinotecan can decrease the size of tumors and also appears to increase the effectiveness of radiation. The purpose of this study is to determine the highest dose of irinotecan that can be given safely in combination with radiation therapy, and to determine the side effects when these two treatments are given together. Irinotecan is approved by the Food and Drug Administration (FDA) for the treatment of colon cancer, but is not approved for cancers of the digestive tract. However, the FDA is allowing its use in this research study.
Condition | Intervention | Phase |
Pancreatic Cancer Gastric Cancer Duodenum Cancer Bile Duct Cancer |
Drug: irinotecan Procedure: radiation therapy |
Phase I |
MedlinePlus related topics: | Cancer Intestinal Cancer Pancreatic Cancer Stomach Cancer |
Drug Information available for: | Irinotecan Irinotecan hydrochloride Pancrelipase Ultrase |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study |
Official Title: | Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers |
Estimated Enrollment: | 20 |
Study Start Date: | December 2000 |
Study Completion Date: | July 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |||||
U.S.C./Norris Cancer Center | |||||
Los Angeles, California, United States, 90033 |
Norris Comprehensive Cancer Center |
Principal Investigator: | Syma Iqbal, M.D. | U.S.C./Norris Comprehensive Cancer Center |
Study ID Numbers: | 0C-00-8 |
First Received: | September 9, 2005 |
Last Updated: | January 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00183846 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|